VolitionRx (NYSE:VNRX) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Thursday. The brokerage set a “sell” rating on the stock.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $2.50 price target on shares of VolitionRx in a report on Wednesday, March 27th.

VolitionRx Trading Down 3.2 %

Shares of VolitionRx stock opened at $0.60 on Thursday. The business’s fifty day simple moving average is $0.89 and its 200 day simple moving average is $0.84. The firm has a market capitalization of $49.24 million, a P/E ratio of -1.18 and a beta of 1.35. VolitionRx has a 12 month low of $0.55 and a 12 month high of $2.10.

VolitionRx (NYSE:VNRX) last issued its quarterly earnings results on Monday, March 25th. The company reported ($0.11) EPS for the quarter. The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.50 million. Analysts predict that VolitionRx will post -0.4 EPS for the current fiscal year.

Institutional Trading of VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Vanguard Group Inc. boosted its position in VolitionRx Limited (NYSE:VNRX) by 4.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 542,444 shares of the company’s stock after buying an additional 22,046 shares during the quarter. Vanguard Group Inc. owned approximately 0.69% of VolitionRx worth $374,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.